Trever G. Bivona

Department of Medicine, University of California, San Francisco

Affiliated withUniversity of California, San Francisco

Research Area

Biography

Trever G. Bivona has not added Biography.
If you are Trever G. Bivona and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 7	2021

Other Publications

Article	Year
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature cell biology\| PubMed ID: 30104724	2018
Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science (New York, N.Y.)\| PubMed ID: 30166458	2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer research\| PubMed ID: 30538120	2019
Immunohistochemistry to Study YAP in Human Tissue Samples. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 30565127	2019
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in molecular medicine\| PubMed ID: 30686761	2019
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current oncology reports\| PubMed ID: 30806814	2019
Polytherapy and Targeted Cancer Drug Resistance. Trends in cancer\| PubMed ID: 30898264	2019
Dampening oncogenic RAS signaling. Science (New York, N.Y.)\| PubMed ID: 30898918	2019
Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer discovery\| PubMed ID: 30992280	2019
Targeting Oncogenic BRAF: Past, Present, and Future. Cancers\| PubMed ID: 31426419	2019
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell reports\| PubMed ID: 31461649	2019
Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers\| PubMed ID: 31533235	2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31548343	2020
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nature communications\| PubMed ID: 32699215	2020
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell\| PubMed ID: 32822576	2020
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current opinion in chemical biology\| PubMed ID: 33418513	2021
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science (New York, N.Y.)\| PubMed ID: 33479121	2021
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell\| PubMed ID: 33848463	2021
Stepwise evolution of therapy resistance in AML. Cancer cell\| PubMed ID: 34171262	2021
Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell reports\| PubMed ID: 34348154	2021